Autonomix Medical Files 8-K for Material Agreement

TL;DR

Autonomix Medical signed a big deal, filing an 8-K. Details TBD.

AI Summary

Autonomix Medical, Inc. announced on November 22, 2024, that it entered into a Material Definitive Agreement. The company also reported other events and filed financial statements and exhibits. The specific details of the agreement and financial information were not provided in this excerpt.

Why It Matters

This filing indicates a significant business development for Autonomix Medical, Inc., potentially impacting its operations and future financial performance.

Risk Assessment

Risk Level: medium — The filing of an 8-K for a material definitive agreement suggests significant events are occurring, but the lack of specific details in this excerpt introduces uncertainty.

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• November 22, 2024 (date) — Date of earliest event reported
• 21 Waterway Avenue, Suite 300 (address) — Principal executive offices
• The Woodlands, TX (location) — Principal executive offices location
• 713-588-6150 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
• $6 — purchase price of each Common Unit was $6.540, and the purchase price of each Pre
• $6.539 — chase price of each Pre-Funded Unit was $6.539. In addition, the Company granted the U
• $6.540 — es A Warrants have an exercise price of $6.540 per share, are immediately exercisable
• $10.0 m — er-allotment option, were approximately $10.0 million, before deducting underwriting di
• $115,000 — or certain out-of-pocket expenses up to $115,000. The Company also issued to the represe

Filing Documents

• amix20241125_8k.htm (8-K) — 35KB
• ex_752262.htm (EX-1.1) — 285KB
• ex_752263.htm (EX-4.1) — 116KB
• ex_752264.htm (EX-4.2) — 118KB
• ex_752265.htm (EX-4.3) — 124KB
• ex_752266.htm (EX-4.4) — 107KB
• ex_752267.htm (EX-99.1) — 12KB
• ex_752268.htm (EX-99.2) — 11KB
• logo01.jpg (GRAPHIC) — 3KB
• logoa.jpg (GRAPHIC) — 2KB
• 0001437749-24-036182.txt ( ) — 1129KB
• amix-20241122.xsd (EX-101.SCH) — 3KB
• amix-20241122_def.xml (EX-101.DEF) — 12KB
• amix-20241122_lab.xml (EX-101.LAB) — 15KB
• amix-20241122_pre.xml (EX-101.PRE) — 12KB
• amix20241125_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On November 22, 2024, Autonomix Medical, Inc. (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with Ladenburg Thalmann & Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the "Underwriters"), in connection with a firm commitment underwritten public offering (the "Offering") of: (i) 458,691 common units (the "Common Units"), each Common Unit consisting of one share of common stock, par value $0.001 per share, of the Company (the "Common Stock") and one series A warrant to purchase one share of Common Stock (the "Series A Warrants"); and (ii) 917,596 pre-funded units (the "Pre-Funded Units"), each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of Common Stock (the "Pre-Funded Warrant") and one Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539. In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and may be exercised at any time until the five-year anniversary of the date of issuance. The Pre-Funded Warrants and Series A Warrants were issued pursuant a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the "Warrant Agency Agreement"). The Offering closed on November 25, 2024. On November 22, 2024, the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The aggregate gr

01. Other Events

Item 8.01. Other Events On November 22, 2024, the Company issued a press release regarding the pricing of the Offering, and on November 25, 2024, the Company issued a press release regarding the closing of the Offering. Copies of such press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated November 22, 202, with Ladenburg Thalmann & Co. Inc. 4.1 Form of Pre-funded Warrant 4.2 Form of Series A Warrant 4.3 Warrant Agency Agreement, dated November 22, 2024, with Equity Stock Transfer, LLC 4.4 Form of Representative's Warrant 99.1 Press Release dated November 22, 2024 99.2 Press Release dated November 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: November 25, 2024

View Full Filing

View this 8-K filing on SEC EDGAR